NASDAQ: ZLAB

Zai Lab Limited

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading business information to the investing public.

If you purchased Zai Lab securities and would like to join the prospective action, please click “Join This Class Action.”

Retainer Agreement
See Full Details
Join This Class Action
If you purchased Zai Lab securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On June 6, 2023, Zai Lab reported phase 3 trials for an oncology therapy it is developing with NovoCure. It said that its tumor treating fields (TTFields) therapy, which uses skin patches to deliver electric fields to areas of the body, when used with standard therapies, met its primary endpoint of three-month improvement in median overall survival time in metastatic non-small cell lung cancer (NSCLC) patients. Further, the company reported that patients with the TTFields therapy has a median overall survival time of 13.2 months compared to 9.9 months with patients who just had standard therapies. However, many of the study participants didn’t use an initial checkpoint inhibitor, which is seen as the leading way to treat NSCLC, thereby allowing for the possibility that the study was highly skewed by comparing TTFields to a lesser therapy.

On this news, Zai Lab’s stock fell $4.88 per share, or 14.55%, on unusually high trading volume, to close at $28.66 per share on June 7, 2023.

Follow us on:
Twitter
Company Name: Zai Lab Limited
Stock Symbol: ZLAB
Class Period: N/A
Court: N/A
Share This Class Action
Join This Class Action

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Case Attorneys

Phillip Kim

New York, Philadelphia Metro

275 Madison Avenue
40th Floor
New York, NY 10016

Tel: (212) 686-1060
Privacy Policy | Accessibility
Scroll to Top